Welcome to our dedicated page for BIOTRICITY news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on BIOTRICITY stock.
Biotricity, Inc. (BTCY) is a medical technology company at the forefront of healthcare innovation. Specializing in biometric data monitoring solutions, Biotricity aims to improve healthcare by developing remote monitoring solutions for chronic disease prevention and management. Its premier product, Bioflux, is an ECG monitoring system used by physicians to diagnose and monitor cardiac patients remotely. Biotricity's Biolife solution extends medical-grade monitoring to the consumer market, empowering users to self-manage chronic conditions through lifestyle changes. With a focus on preventive healthcare, Biotricity's R&D efforts aim to put health management directly into the hands of individuals, easing the burden on the healthcare system.
Rhea-AI Summary
Biotricity Inc. announces high demand for its latest diagnostic product, Biotres Pro, expected to increase revenue by up to 10% in fiscal 2025. The device has sold out in its initial production run, with customers placing pre-orders for the next run. Dr. Waqaas Al-Siddiq, Founder and CEO, anticipates that Biotres Pro will accelerate the company's path to breakeven.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
-
Rhea-AI Summary
Biotricity Inc. (BTCY) launches a groundbreaking cardiac monitoring pilot program in collaboration with a prestigious hospital group comprising 9 hospitals and 10 clinics. The program aims to optimize patient interaction protocols and streamline data collection processes, showcasing the impact of Biotricity's technology suite. This initiative follows strategic partnerships with leading Group Purchasing Organizations (GPOs) totaling $264 billion, providing access to 90% of hospitals nationwide. The CEO, Dr. Waqaas Al-Siddiq, emphasizes the transformative potential of their solutions in redefining disease profiling, patient management, and preventative care methodologies. With a focus on a $35 billion market opportunity, Biotricity is positioned as an innovative leader in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.54%
Tags
-
Rhea-AI Summary
Biotricity Inc. (NASDAQ:BTCY) launches a cardiac monitoring pilot program with a major hospital network, spanning over 50 hospitals across multiple states. The program aims to showcase the value of Biotricity's solutions and potentially lead to a widespread commercial rollout. Dr. Waqaas Al-Siddiq, Biotricity's CEO, highlights the company's enhanced market reach through partnerships with Group Purchasing Organizations (GPOs) and emphasizes the scalability of their hardware and software solutions. The pilot program will focus on data collection, patient interaction protocols refinement, and technology suite enhancement to drive innovation in predictive monitoring tools and disease prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.45%
Tags
News
Rhea-AI Summary
Biotricity Inc. announces a strategic partnership in neurology to conduct cardiac screenings, aiming to improve patient care and reduce costs. The company plans to build a broader cardiac screening network to support patients with co-morbidities, enhancing market reach within the healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
-
Rhea-AI Summary
RedChip Companies will feature interviews with LOBO EV Technologies and Biotricity, Inc. on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. LOBO EV, a Chinese EV manufacturer, offers a range of electric vehicles and software services, poised for growth in the $16 billion e-bike market. Biotricity, a leader in remote cardiac care, targets a $35 billion market with its innovative technology and strong market presence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
-
Rhea-AI Summary
Biotricity Inc. (NASDAQ:BTCY) announces a strategic partnership with a leading Group Purchasing Organization (GPO) to enhance market reach and drive growth in the healthcare technology sector. The partnership grants access to 90% of all hospitals in the U.S., representing $264 billion in purchasing power. Biotricity aims to revolutionize healthcare with cutting-edge remote cardiac monitoring solutions, anticipating robust growth amid increasing healthcare expenditures and an aging population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
Rhea-AI Summary
Biotricity Inc. (BTCY) partners with Health Aid Africa for a charity concert to promote healthcare access and awareness. The event aims to revolutionize cardiac care, combining music, technology, and philanthropy on a global scale.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.55%
Tags
-
Rhea-AI Summary
Biotricity Inc. announces the expansion of its Cardiac AI platform, aiming to file for FDA clearance by the end of the year. The Healthcare AI Market is projected to reach $208.2 billion, with the remote patient monitoring market expected to hit $96.67 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
-
Rhea-AI Summary
Biotricity Inc. (BTCY) announces a strategic partnership with a top Group Purchasing Organization (GPO), expanding its market access to over 3,000 hospitals in the US with a purchasing power of $160 billion. This move highlights Biotricity's commitment to delivering cutting-edge healthcare solutions, driving positive clinical outcomes, and maximizing economic returns in the rapidly growing healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Better Therapeutics offers a groundbreaking approach to managing cardiometabolic diseases with its FDA-authorized product AspyreRx™, showcasing significant outcomes in treating type 2 diabetes. Biotricity revolutionizes cardiac care with remote diagnostic solutions, capturing an 8% market share in cardiology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
FAQ
What is the current stock price of BIOTRICITY (BTCY)?
The current stock price of BIOTRICITY (BTCY) is $0.2776 as of November 21, 2024.
What is the market cap of BIOTRICITY (BTCY)?
The market cap of BIOTRICITY (BTCY) is approximately 14.3M.
What is Biotricity, Inc.?
Biotricity, Inc. is a medical technology company focused on developing biometric data monitoring solutions for chronic disease prevention and management.
What are some of Biotricity's products?
Biotricity's premier product is Bioflux, an ECG monitoring system used for diagnosing and remotely monitoring cardiac patients. The company also offers Biolife, a consumer-focused solution for self-managing chronic conditions.
What is the vision of Biotricity, Inc.?
Biotricity aims to empower individuals by providing innovative solutions for preventive healthcare, ultimately enabling users to take control of their health and manage critical conditions effectively.
How does Biotricity contribute to the healthcare industry?
Biotricity's focus on remote monitoring and chronic care management bridges the gap in healthcare services, offering diagnostic and post-diagnostic solutions for chronic conditions, particularly in the cardiology sector.
BIOTRICITY INC
Nasdaq:BTCY
BTCY Rankings
BTCY Stock Data
14.29M
14.43M
40.89%
2.11%
2.07%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States of America
REDWOOD CITY